Trastuzumab deruxtecan in advanced breast cancer patients with brain metastases or leptomeningeal metastases
•Trastuzumab deruxtecan showed superior intracranial overall response rate (ORR) and median progression-free survival (mPFS) than controls in both stable and active brain metastases.•DEBBRAH, TUXEDO-1, and DESTINY-Breast 12 confirm durable intracranial activity in brain metastases with trastuzumab deruxtecan.•Real-world ROSET-BM data reported median overall survival (OS, 27.0 months) and mPFS (14.6 months) in active BM, reinforcing T-DXd efficacy.•In leptomeningeal metastases (LM) cohorts, T-DXd achieved clinical benefit rate (71.4-100%), mOS (10.4-13.3 months), and mPFS (8.9-17.5 months) across studies.•For active BM, local intervention plus T-DXd (or tucatinib combination) is recommended based on efficacy stratification.
Authors
- Liuliu Quan (ORCID: https://orcid.org/0000-0003-4599-6174)
- Min Dou (ORCID: https://orcid.org/0000-0003-0987-5578)
- Peng Yuan (ORCID: https://orcid.org/0000-0003-4627-8203)
- Xiao Guan
- Jian Yue (ORCID: https://orcid.org/0000-0002-1579-5593)
- Die Sang (ORCID: https://orcid.org/0009-0001-9637-4220)
- Jinsong Liu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Renji Hospital (CN)
- National Cancer Center (US)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1016/j.cpt.2025.05.003
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Fundamental Research Funds for the Central Universities